Venlafaxine Hydrochloride Tablet, Extended Release
Product Images NDC 31722-124

This is a medication guide for Venlafaxine Extended-Release tablets, containing 30 tablets, each with 150mg of venlafaxine hydrochloride USP. The usual dosage is once daily, with dosage information available in the package insert. The tablets should be stored between 15°-30°C (59°-86°P)fse USP Contoled Room Temperature], and protected from moisture and humidity. This medication is manufactured by Ascent Pharmaceutical, Inc. for Camber Pharmaceutical, Inc. and a medication guide is available at tpcamberphara com/medicti.*

This is a medication called "Venlafaxine Extended-Release Tablets." It comes in a bottle of 90 tablets and each tablet contains 150mg of venlafaxine hydrochloride. The recommended dosage is one tablet per day. The medication should be stored between 16-30°C and protected from moisture and humidity. The manufacturer is Ascent Pharmaceuticals and it is distributed by Camber Pharmaceuticals. An instruction guide is available online at tpicamberphma.com/medicaton-quides.*

This is a description of Venlafaxine Extended-Release Tablets. This medication is used to treat depression and anxiety. Each extended-release tablet contains venlaaxine hydrochloride, USP equivalent to 225 mg of venlafaxine. It is important for authorized dispensers to give patients the attached Medication Guide. The recommended dosage is once daily, and additional dosage instructions are available in the package insert. The medication should be stored at a temperature of 25°C (77°F) with permissible excursions to 16° - 30°C (69° - 86°F) at USP Controlled Room Temperature. The medication should be protected from moisture and humidity. This medication is manufactured by Ascent Pharmaceuticals, Inc, Central Islip, NY 11722, and manufactured for Camber Pharmaceuticals, Inc, Fiscataway, NJ 08854.*

This is a description of Venlafaxine extended-release tablets, containing 90 tablets of 225 mg each. The authorized dispenser should provide the enclosed medication guide to the patient. The standard dosage is one extended-release tablet per day, and the medication should be stored at 25°C. Ascent Pharmaceuticals Inc. from Central Islip, NY, manufactures them for Camber Pharmaceuticals Inc. from Fiscataway, NJ. A medication guide can be found at tpicamberpharma.com/medication-guides.*

Each extended-release tablet contains Venlafaxine Hydrochloride equivalent to 37.5 mg of Venlafaxine. It is recommended to take only once a day. The usual dosage details can be found in the package insert. Store at temperatures between 16-30°C (69°-86°F), protect from moisture and humidity. For more information about usage, visit http:/camberpharma.cor, and each time the tablet is dispensed, provide the patient with the medication guide. This medication is manufactured by Ascent Pharmaceuticals, Inc., Central Islip, NY, and is distributed by Camber Pharmaceuticals, Inc., Piscataway, NJ, and is available only through a prescription.*

Each extended-release tablet contains 37.5mg of Venlafaxine Hydrochloride, USP. It is usually taken once a day, with dosage information available in the package insert. The tablets should be stored between 16-30°C (69° - 86°F) and protected from moisture and humidity. Camber Pharmaceuticals Inc. manufactures these tablets, and a medication guide should be given to the patient upon dispensing.*

Each tablet of venlafaxine hydrochloride contains 75mg of the active ingredient. The usual dosage is once daily and detailed dosage information can be found in the package insert. The tablets should be stored at a temperature range of 15-30°C. These extended-release tablets are manufactured by Ascent Pharmaceutical, Inc. Dispensers should provide patients with the attached Medication Guide. This medication requires a prescription.*

The text describes a table named "Table 1" which includes numerical data related to the difference in the number of cases of suicidality per 1000 patients treated with drugs compared to placebo. The data is categorized by age range and shows that patients under 18 and 18-24 years old are more likely to experience an increase in cases of suicidality while patients between the ages of 25-64 experience fewer cases when treated with drugs compared to placebo.*

Table 2 shows the percentage of sustained elevations in systolic blood pressure in premarketing studies of Venlafaxine Hydrochloride Extended-Release Capsule. The data is segregated by indication and dosage. Table 3 shows the incidence of sustained elevations in systolic blood pressure in Venlafaxine Hydrochloride Immediate-Release Tablet studies, grouped by dosage. The data in Table 3 indicates that the incidence of sustained elevations in systolic blood pressure increases with dosage.*

This is a table showing the final changes in supine systolic and diastolic blood pressure in patients treated with Venlafaxine Hydrochloride Extended-Release Capsules and Placebo, based on indication, study duration, and dose in placebo-controlled trials. The results show the mean changes from baseline in mm Hg.*

This is a table showing the incidence of insomnia and nervousness in placebo-controlled major depressive disorder and other trials for Venlafaxine Hydrochloride Extended-Release Capsules. The table compares the percentages of symptoms in patients who took Venlafaxine Hydrochloride Extended-Release Capsules versus those who took placebo.*

The text seems to be a table showing the incidence of treatment-emergent adverse reactions during short-term placebo-controlled clinical trials with Venlataxine Hydrochloride Extended-Release Capsules in patients with Major Depressive Disorder. The table includes the number of reported cases and percentages for each adverse reaction, such as hypertension, vomiting, weight loss, and agitation. Therefore, it's a useful description of the incidence of adverse reactions to this medication during clinical trials.*

The text contains only a chemical formula for "H,CO- SHCI" and the name of a chemical compound "venlafaxine hydrochloride". It does not provide any additional information or context to generate a meaningful description.*

This text appears to be describing potential warning signs or symptoms of mental health issues or distress, including thoughts of suicide or self-harm, changes in mood or behavior, and physical symptoms like eye pain or trouble sleeping. It is not clear from this text what specific context or condition these symptoms may be associated with, but it suggests a need for further evaluation and potential intervention or treatment.*